Assessing the current proteomics field

Russell Publishing Ltd
Court Lodge
Hogtrough Hill
Brasted
Kent TN16 1NU. UK
Registered in England
No. 2709148
Registered office as above.
VAT No. GB 577 897847

You are here: Home » Functional Genomics » Assessing the current proteomics field

publication date: Apr 7, 2008

There has been much interest in the promise of proteomics to deliver biomarkers with utility for disease diagnosis and classification, and for assessing therapeutic efficacy and monitoring disease progression. However recently, particularly in the past year, expressions of concern have started to emerge regarding the paucity of protein biomarkers that have reached the stage of FDA approval or at least that have been sufficiently validated in independent studies. Therefore, a clear understanding of the current situation with respect to biomarkers and proteomics would be useful in assessing whether the field does hold promise and is ready to ‘deliver’ or whether effort should be focused elsewhere. The observations and derived conclusions presented here are intended to assess the current status of the field.

Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive

Click here to join